May 10, 1993

Fluconazole-Resistant Candida albicans After Long-term Suppressive Therapy

Author Affiliations

From the Department of Internal Medicine, Tucson (Ariz) Hospital Medical Education Program (Dr Sanguineti); the Department of Internal Medicine, Section of Infectious Disease, Department of Family Medicine, University of Arizona College of Medicine (Dr Carmichael); and the College of Pharmacy, University of Arizona, Tucson (Dr Campbell).

Arch Intern Med. 1993;153(9):1122-1124. doi:10.1001/archinte.1993.00410090068008

Candida albicans is generally considered to be susceptible, in vivo, to fluconazole. In the population infected with human immunodeficiency virus, recurrent bouts of oral and esophageal candidiasis have led to increasing use of fluconazole for long-term prophylaxis. With prolonged therapy, the issue of developing resistance emerges. We report a case of fluconazole-resistant C albicans esophagitis that developed after fluconazole was used for more than 600 days.

(Arch Intern Med. 1993;153:1122-1124)